Kohei Shitara Selected Research

Immune Checkpoint Inhibitors

9/2022	Characteristics and clinical outcomes of patients with advanced gastric or gastroesophageal cancer treated in and out of randomized clinical trials of first-line immune checkpoint inhibitors.
2/2022	The New Era of Immunotherapy in Gastric Cancer.
1/2022	Ascites and resistance to immune checkpoint inhibition in dMMR/MSI-H metastatic colorectal and gastric cancers.
12/2021	Hypothyroidism and hypopituitarism as immune-related adverse events due to lenvatinib plus pembrolizumab therapy in the immediate postoperative period after laparoscopic hepatectomy for liver metastases from gastric cancer: a case report.
12/2021	TAS-116 (Pimitespib), an Oral HSP90 Inhibitor, in Combination with Nivolumab in Patients with Colorectal Cancer and Other Solid Tumors: An Open-Label, Dose-Finding, and Expansion Phase Ib Trial (EPOC1704).
1/2021	Cancer immunotherapy with PI3K and PD-1 dual-blockade via optimal modulation of T cell activation signal.
1/2021	Current status of immunotherapy for advanced gastric cancer.
1/2021	First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial.
11/2020	The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies.
1/2020	The Impact of Molecular Subtype on Efficacy of Chemotherapy and Checkpoint Inhibition in Advanced Gastric Cancer.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Kohei Shitara Research Topics

Disease

121	Stomach Neoplasms (Stomach Cancer) 08/2022 - 10/2005
108	Neoplasms (Cancer) 09/2022 - 01/2008
44	Colorectal Neoplasms (Colorectal Cancer) 01/2022 - 12/2005
31	Neoplasm Metastasis (Metastasis) 01/2022 - 01/2006
27	Adenocarcinoma 08/2022 - 09/2011
14	Neutropenia 01/2021 - 02/2011
12	Disease Progression 01/2022 - 05/2011
7	Esophageal Neoplasms (Esophageal Cancer) 11/2012 - 08/2006
6	Interstitial Lung Diseases (Interstitial Lung Disease) 05/2022 - 01/2006
6	Microsatellite Instability 02/2022 - 01/2021
6	Ascites 01/2022 - 11/2009
6	Breast Neoplasms (Breast Cancer) 01/2021 - 07/2006
6	Anemia 01/2021 - 06/2007
5	Pneumonia (Pneumonitis) 05/2022 - 01/2006
4	Diarrhea 07/2022 - 05/2011
4	Gastrointestinal Neoplasms (Gastrointestinal Cancer) 01/2022 - 12/2005
4	Febrile Neutropenia 01/2022 - 01/2017
4	Fatigue 12/2021 - 07/2011
4	Fever (Fevers) 12/2021 - 01/2006
4	Colonic Neoplasms (Colon Cancer) 07/2011 - 07/2007
3	Rectal Neoplasms (Rectal Cancer) 04/2021 - 07/2008
3	Thrombocytopenia (Thrombopenia) 01/2021 - 08/2011
3	Leukopenia 01/2020 - 08/2011
3	Anorexia 01/2020 - 07/2011
3	Hemorrhage 01/2018 - 08/2015
3	Jaundice (Icterus) 08/2011 - 07/2009
3	Dyspnea (Shortness of Breath) 03/2011 - 01/2006
3	Pancreatic Neoplasms (Pancreatic Cancer) 01/2008 - 11/2005
2	Sudden Death 01/2022 - 01/2019
2	Liver Failure 01/2022 - 06/2008
2	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2021 - 09/2017
2	Exanthema (Rash) 01/2021 - 01/2020
2	Vomiting 01/2020 - 01/2019
2	Nausea 01/2020 - 11/2016

Drug/Important Bio-Agent (IBA)

23	pembrolizumabIBA 08/2022 - 01/2018
20	Paclitaxel (Taxol)FDA LinkGeneric 07/2022 - 01/2006
20	Irinotecan (Camptosar)FDA LinkGeneric 01/2020 - 10/2005
19	Oxaliplatin (Eloxatin)FDA LinkGeneric 08/2022 - 12/2005
18	Immune Checkpoint InhibitorsIBA 09/2022 - 09/2017
18	Trastuzumab (Herceptin)FDA Link 02/2022 - 07/2006
17	Cisplatin (Platino)FDA LinkGeneric 08/2022 - 08/2006
17	Biomarkers (Surrogate Marker)IBA 08/2022 - 06/2012
15	Fluorouracil (Carac)FDA LinkGeneric 11/2021 - 12/2005
14	trifluridine tipiracil drug combinationIBA 01/2022 - 01/2016
14	Bevacizumab (Avastin)FDA Link 01/2021 - 07/2008
13	Monoclonal AntibodiesIBA 02/2022 - 10/2016
13	NivolumabIBA 02/2022 - 01/2019
13	Cetuximab (Erbitux)FDA Link 01/2020 - 04/2009
12	human ERBB2 proteinIBA 08/2022 - 05/2011
12	RamucirumabIBA 01/2021 - 02/2015
9	trastuzumab deruxtecanIBA 05/2022 - 01/2019
9	Docetaxel (Taxotere)FDA Link 12/2021 - 11/2006
8	Pharmaceutical PreparationsIBA 05/2022 - 06/2006
8	Capecitabine (Xeloda)FDA Link 01/2022 - 12/2005
8	Leucovorin (Folinic Acid)FDA Link 11/2021 - 07/2007
6	regorafenibIBA 01/2022 - 12/2016
6	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2021 - 02/2015
6	PlatinumIBA 09/2020 - 07/2007
6	S-1 plus cisplatinIBA 01/2016 - 11/2010
5	B7-H1 AntigenIBA 08/2022 - 10/2018
5	ErbB Receptors (EGF Receptor)IBA 01/2022 - 04/2015
5	LigandsIBA 01/2021 - 05/2017
4	napabucasinIBA 07/2022 - 05/2019
4	Immunoconjugates (Immunoconjugate)IBA 05/2022 - 11/2017
4	AntibodiesIBA 02/2022 - 05/2017
4	Cytotoxins (Cytolysins)IBA 10/2021 - 06/2011
4	Panitumumab (Vectibix)FDA Link 10/2020 - 04/2009
4	taxaneIBA 02/2020 - 06/2006
4	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 01/2020 - 02/2015
3	lenvatinibIBA 01/2022 - 01/2020
3	Circulating Tumor DNAIBA 10/2021 - 12/2016
3	Taxoids (Taxanes)IBA 03/2021 - 06/2011
3	Epidermal Growth Factor (EGF)IBA 01/2021 - 07/2012
3	Ado-Trastuzumab EmtansineIBA 02/2020 - 10/2016
3	DNA (Deoxyribonucleic Acid)IBA 01/2020 - 06/2018
3	130-nm albumin-bound paclitaxelIBA 01/2019 - 01/2017
3	Gemcitabine FDA Link 01/2017 - 11/2005
3	thiamine triphosphorate (TTP)IBA 04/2014 - 07/2007
2	Reactive Oxygen Species (Oxygen Radicals)IBA 07/2022 - 05/2022
2	TAS-116IBA 12/2021 - 01/2019
2	dUTP pyrophosphataseIBA 01/2021 - 01/2019
2	Immune Checkpoint ProteinsIBA 01/2021 - 01/2018
2	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2021 - 01/2019
2	Proteins (Proteins, Gene)FDA Link 01/2021 - 01/2019
2	AntigensIBA 01/2021 - 10/2009
2	TAS-114IBA 01/2021 - 01/2019
2	Phosphotransferases (Kinase)IBA 01/2020 - 01/2019

Therapy/Procedure

102	Drug Therapy (Chemotherapy) 09/2022 - 12/2005
61	Therapeutics 01/2022 - 10/2005
19	Combination Drug Therapy (Combination Chemotherapy) 01/2020 - 07/2006
10	Adjuvant Chemotherapy 01/2022 - 11/2008
9	Immunotherapy 02/2022 - 01/2018
7	Gastrectomy 01/2022 - 10/2007
7	Precision Medicine 03/2021 - 09/2018
7	Radiotherapy 01/2020 - 06/2007
6	Chemoradiotherapy 11/2012 - 08/2006
4	Lymph Node Excision (Lymph Node Dissection) 01/2020 - 07/2006
3	Aftercare (After-Treatment) 01/2018 - 07/2007
2	Neoadjuvant Therapy 01/2022 - 10/2007
2	Adjuvant Chemoradiotherapy 04/2021 - 07/2006